Drug recall · August 7, 2013
Enablex recall
Why: Failed Impurities/Degradation Specifications: unspecified degradation product
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Enablex (darifenacin) Extended Release Tablet, 15 mg per tablet. Physician Sample 7 Tablets bottle, Rx only, Mfd by: Novartis Pharma Stein AG, Stein, Switzerland, NDC 0078-9420-07
- Lots / codes
Lot F1002 - Exp.12/13
- Quantity
- 188,600 bottles
- Company
- Warner Chilcott US LLC, Rockaway, NJ
- Distribution
- Nationwide
- Initiated
- May 17, 2013 · Voluntary: Firm initiated
- Classified
- July 26, 2013
- Reported
- August 7, 2013
- Ended
- November 30, 2015
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Darifenacin
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.